Hormone therapyFDA-approvedSecond-line
Zytiga
Generic name: abiraterone
How it works
Blocks production of androgens, hormones that fuel prostate cancer growth.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 65% of men with metastatic prostate cancer achieved an objective response, with median overall survival of approximately 15 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Two Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median prostate cancer-specific survival from the initiation of DTX was 16.1 months in the ENZ-DTX group and 25.3 months in the ABI-DTX group. | Source → |
| Olaparib + Abiraterone for Metastatic Prostate Cancer: Real-World Study | Prostate Cancer | preclinical | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | phase-2 | The 1-year radiographic progression-free survival rate was 77.7% (95% CI: 63.4-95.3%). | Source → |
| Study Examines Effectiveness of Prostate Cancer Treatments in Patients with History of Other Cancers | Prostate Cancer | phase-3 | Within the HOC+ group, OS was significantly worse with ENZ than with ABI (median 16.0 vs. 30.5 months; HR 3.27; 95% CI 1.08-9.89; p = 0.0354) | Source → |
| Evaluating a New Medicine for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Abiraterone, Apalutamide, and Prednisone in Treating Hormone-Naive Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 38.6 months in the niraparib + AAP group versus 8.3 months in the placebo + AAP group. | Source → |
| Testing Xaluritamig Plus Abiraterone for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Low-Dose Abiraterone May Be a Feasible Alternative for Prostate Cancer Treatment | Prostate Cancer | phase-3 | Median PSA-PFS was 5.7 months with low-dose versus 3.8 months with standard-dose AA. | Source → |
| Capivasertib and Abiraterone for Prostate Cancer with PTEN Deficiency | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing a New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone Acetate May Help Fight Prostate Cancer by Triggering Stress Response | Prostate Cancer | lab-study | AA induced concentration/time-dependent cytotoxicity in LNCaP cells (24 h IC₅₀ = 4.8 μM) and 22Rv1 cells (24 h IC₅₀ = 15.2 μM) and proliferation decreased by 54.1% and 7.3% at 4.8 μM, respectively. | Source → |
| Genetic Link to Abiraterone Dosage Identified in Prostate Cancer Study | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Enzalutamide Show Similar Outcomes in Prostate Cancer | Prostate Cancer | observational | Median overall survival was 36.2 months for both abiraterone and enzalutamide. | Source → |
| Combining Medications May Help Prostate Cancer Patients | Prostate Cancer | phase-3 | The primary endpoint was met, with a significant improvement in radiographic progression-free survival observed, with a hazard ratio of 0.63. | Source → |
| Combining Trastuzumab Deruxtecan and Abiraterone Shows Promise in Prostate Cancer | Prostate Cancer | observational | — | Source → |
| Enzalutamide May Offer Better Survival for Prostate Cancer Patients | Prostate Cancer | observational | Enzalutamide-treated patients had longer overall survival in the first-line setting (HR: 0.84) and the second-line setting (HR: 0.88). | Source → |
| New Delivery System for Prostate Cancer Treatment Shows Promise | Prostate Cancer | lab-study | The dissolution study demonstrated significantly higher ABT release from ABT-ssSNEDDS in comparison to free ABT after 2 h in pH 1.2 and 6.8 pH buffer. | Source → |
| Comorbidities Affect Abiraterone Treatment in Prostate Cancer | Prostate Cancer | meta-analysis | — | Source → |
| Modified Monitoring of Abiraterone May Reduce Liver Damage in Prostate Cancer Patients | Prostate Cancer | observational | — | Source → |
| Comparing Prostate Cancer Treatments: Abiraterone, Enzalutamide, and Apalutamide | Prostate Cancer | observational | Abiraterone was significantly better in 99% PSA decline achievement compared to apalutamide (72% vs. 57%, p = 0.003). | Source → |
| Abiraterone Resistance in Prostate Cancer Linked to CENPK Splice Variant | Prostate Cancer | lab-study | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| Abiraterone Treatment in Prostate Cancer: Early Response Matters | Prostate Cancer | phase-2 | Those patients with hetero-responding disease had significantly different PFS compared to the responding and non-responding groups (hazard ratio: responding group = reference, hetero-responding group = 4.0, non-responding group = 5.8; p < 0.0001). | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | observational | Patients initiating enzalutamide had a 0.90-month longer overall survival compared to those initiating abiraterone acetate at 4 years. | Source → |
| Long-term effects of prostate cancer treatment studied | Prostate Cancer | phase-2 | A significant association between higher abiraterone acetate concentrations and better clinical benefit was observed (p = 0.041). | Source → |
| Abiraterone Efficacy Predicted by Prostate Cancer Biomarker | Prostate Cancer | observational | The median PSA-PFS was 11.43 months versus 26.43 months in patients with KI67 ≥ 30% versus those with KI67 < 30%. | Source → |
| Abiraterone May Cause Heart Rhythm Problem in Some Patients | Prostate Cancer | observational | — | Source → |
| New Treatment Combination for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median radiographic progression-free survival was 25 months for olaparib plus abiraterone versus 17 months for placebo plus abiraterone. | Source → |
| New Study Compares Effectiveness of Two Cancer Drugs for Prostate Cancer | Prostate Cancer | phase-3 | The median PSA response rate was -65.4% with abiraterone and -78.8% with enzalutamide. | Source → |
| Genetic variant linked to poorer prostate cancer treatment outcomes | Prostate Cancer | observational | A total of 54 patients (20%) had the variant, which was associated with a significantly worse overall survival (HR = 1.71, 95% CI 1.09 - 2.68, p = 0.019) and time to progression (HR = 1.50, 95% CI 1.08 - 2.09, p = 0.016), and was related with a significantly less frequent PSA response (OR = 0.48, 95% CI 0.24 - 0.96, p = 0.038). | Source → |
| Radiation Therapy and Medication Combination Shows Promise for Prostate Cancer | Prostate Cancer | phase-2 | Biochemical response was detected in 79.6% of patients in the experimental arm, compared to 68.3% in the control arm. | Source → |
| Abiraterone Acetate May Be Better Than Docetaxel for Prostate Cancer | Prostate Cancer | observational | The abiraterone acetate group demonstrated significantly better progression-free survival (PFS) than the docetaxel group (not reached vs. 15.1 months: hazard ratio = 0.37; 95% confidence interval = 0.28-0.50; P < .001). | Source → |
| New Study Links Certain Prostate Cancer Drugs to Cardiovascular Risks | Prostate Cancer | observational | — | Source → |
| New Hormonal Agents May Help Some Prostate Cancer Patients | Prostate Cancer | phase-3 | AAP seems to be effective in improving OS among patients with VM (hazard ratio, HR: 0.58, 95% CI, 0.40-0.84, P = .004 for AAP). | Source → |
| Abiraterone Alone May Be as Effective as Combination Therapy for Prostate Cancer | Prostate Cancer | observational | Patients receiving abiraterone alone had a median PSA reduction of 80.2%. | Source → |
| Apalutamide May Help Prostate Cancer Patients Faster Than Abiraterone | Prostate Cancer | observational | Patients initiated on apalutamide were 53% more likely to achieve PSA90 than those initiated on abiraterone acetate within 6 months. | Source → |
| New Combination Therapy Shows Promise for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 16.6 months in the niraparib + AAP group compared with 10.9 months in the placebo + AAP group. | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median time to castration-resistant prostate cancer in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). | Source → |
| Combining Cancer Drugs May Be More Effective Than Using Them Alone | Prostate Cancer | lab-study | — | Source → |
| Rare Side Effect of Abiraterone Treatment in Prostate Cancer Patients | Prostate Cancer | observational | — | Source → |
| Traditional Chinese Medicine Enhances Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Combining Two Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-1 | Nine participants (33%) showed a 20% or greater decrease in prostate-specific antigen during study treatment. | Source → |
| Triplet Therapy Shows Promise for Prostate Cancer Treatment | Prostate Cancer | meta-analysis | Triplet therapy with darolutamide or abiraterone with docetaxel and ADT improved overall survival, with a hazard ratio of 0.70 (95%CI 0.61-0.80) compared to docetaxel+ADT. | Source → |
| Radiotherapy and Abiraterone Combination for Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Approach to Treatment Prolongs Effectiveness in Prostate Cancer | Prostate Cancer | phase-2 | The study cohort had significantly improved median time to progression (TTP; 33.5 months; p<0.001) and median overall survival (OS; 58.5 months; hazard ratio, 0.41, 95% confidence interval (CI), 0.20-0.83, p<0.001) compared to 14.3 and 31.3 months in the SOC cohort. | Source → |
| Abiraterone and Docetaxel Compared in Prostate Cancer Treatment | Prostate Cancer | observational | The ABI group had a significantly better castration-resistant prostate cancer (CRPC)-free survival than the DOC group [hazard ratio (HR), 0.53; 95% confidence interval (CI), 0.34-0.82]. | Source → |
| Prolactin Levels May Predict Response to Prostate Cancer Treatment | Prostate Cancer | observational | Patients with lower baseline PRL levels responded better to AA than those with higher baseline PRL levels, with a PSA reduction of 66.7% vs. 25.8% (p = 0.001). | Source → |
| Adding Docetaxel or Abiraterone to Prostate Cancer Treatment May Improve Survival | Prostate Cancer | phase-3 | Patients receiving upfront ABI had significantly better CRPCFS than those receiving ADT/CAB or upfront DOC [hazard ratio (HR) 0.39; 95% CI 0.27-0.56]. | Source → |
| Combining Two Compounds May Help Treat Prostate Cancer | Prostate Cancer | lab-study | The combination of abiraterone acetate and apigenin significantly inhibited LNCaP and PC3 cell survival in a manner more marked than observed with either single treatment. | Source → |
| Abiraterone May Be More Effective Than Other Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median time to castration resistance was not reached in the abiraterone group, but it was significantly longer than in the other groups. | Source → |
| Combination Therapy Improves Survival in High-Risk Prostate Cancer | Prostate Cancer | meta-analysis | 6-year metastasis-free survival was 82% in the combination-therapy group and 69% in the control group. | Source → |
| Comparing Costs and Adherence to Abiraterone Treatment for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing Two Cancer Drugs for Advanced Prostate Cancer | Prostate Cancer | observational | — | Source → |
| Comparing Heart Risks of Two Prostate Cancer Treatments | Prostate Cancer | observational | — | Source → |
| Gene Changes in Blood May Predict Prostate Cancer Treatment Outcomes | Prostate Cancer | phase-2 | Plasma tumor DNA detection was associated with shorter overall survival (hazard ratio (HR): 2.89, 95% confidence intervals (CI): 1.77-4.73, P ≤ 0.0001) and progression-free survival (HR: 2.05; 95% CI: 1.36-3.11, P < 0.001). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.